1 Male Menopause: Disease or Pseudoscience? March 4, 2015 story: FDA to require warning on labels of testosterone products ; web William E. Winter, MD University of Florida Departments of Pathology and Pediatrics
2 Learning objectives: At the conclusion of this presentation, the laboratorian will be able to: 1. List the forms of testosterone (T) that circulate. 2. Explain how total and free T are best measured. 3. Describe how free T falls with advancing age. 4. Recall the symptoms of late-onset hypogonadism. 5. Diagnose late-onset hypogonadism. 6. Anticipate the clinical demand for T testing. 7. Explain the risks of T replacement. 8. Plan appropriate monitoring for men treated w/ T. 9. Discuss the benefits and risks of T replacement tx.
3 To fulfill your responsibilites as a man, despite your insecurities and constant ability to place yourself in embarrasing and un-manly scenarios.
4 Testosterone results in 45 minutes!
5 In what forms does testosterone circulate in the body? Free 2% Biologically active Bound Albumin - Loosely (weakly) bound 54% 98% SHBG - Tightly bound* 44% Bioavailable T (BAT) * Precipitable w/ ammonium sulfate (T total T ASP = BAT) Effect of androgens on SHBG: Decr. (-- > incr. free T) ASP = ammonium sulfate precipitable testosterone; T distribution reference: Lepage R. Measurement of testosterone and its sub-fractions in Canada. Clin Biochem Feb;39(2):
6 How should testosterone be measured? Age group Adolescent males and adult men Children and women Method Immunoassay is satisfactory Mass spectroscopy (need lower limits of detection)
7 How can free testosterone be determined? Dialysis equilibrium Ultrafiltration < --- definitive method (labor intensive) < --- definitive method (labor intensive) Analog methods Free androgen index Calculated from total T & SHBG
8 How can free testosterone best be determined in routine clinical laboratories? Total T & SHBG (+/- albumin) --- > calculate free T Concentration Testosterone = FT(free) + Alb-bound-T + [SHBG]-bound-T Testosterone = [S] + [S A ] + [SP] Albumin [S A ] = constant = K A x C onc. Alb = 3.6x10 4 x 43g/l = 22.4 [S] =(molecular weight alb.) K A = = 3.6x104 for an average albumin conc. of 4.3 g/dl or [S A ] = [S] [S] + [S A ] = ( )[S] = [S] (1) SHBG [P] = free SHBG [SP] = steroid bound SHBG K = 10 9 M [S] +[P] «[SP] or [S] = [SP] (2) [P] [K] [P] + [SP] = [SHBG] or [P] = [SHBG] [SP] (3) Bioavailable [Bio T] = [S] + [S A ] Source: J Clin Endocrinol Metab 84: , 1999 A critical evaluation of simple methods for the estimation of free testosterone in serum
9 When should testosterone be measured during the day? Age PM (1600) versus AM (0800)T y/o 20-25% lower 70 y/o 10% lower 2008 Guidelines: 7 AM 11 AM
10 What are the reference intervals for testosterone? Developmental Testosterone Stage (ng/dl) I <3 II <3-432 III IV V Adult male >19 y Source: Lab Corp
11 1143 Japanese men y/o The mean total T by age range decreases only to 80% of the young adult mean even during presenile and senile periods, when LOH occurs most frequently. International Journal of Urology (2009) 16, ; LOH = late-onset hypogonadism
12 1143 Japanese men y/o...free T level shows a linear decrease with aging and drops to 50% of the young adult mean. International Journal of Urology (2009) 16,
13 Critical issues in measuring testosterone & FT 1. Reference intervals among laboratories should NOT be interchanged (need lab-specific ref intervals). 2. There is uncertainty in all methods & measurements. 3. There is intra-individual variation. 4. For repeated measurements, use the same lab. 5. Measure in the AM (and the ~same time w/ every repeated measurement). 6. Low T dx (T & SHBG) requires confirmation: 2 samples 2 wks apart w/ CV i <20% (CV i =>20% - repeat again).
14 What are the symptoms of late-onset hypogonadism? (i) LOH is a syndrome characterized primarily by: (1)The easily recognized features of diminished sexual desire (libido) and erectile quality and frequency, particularly nocturnal erections, (2) Changes in mood with concomitant decreases in intellectual activity, cognitive functions, spatial orientation ability, fatigue, depressed mood and irritability, (3) Sleep disturbances, (4) Decrease in lean body mass with associated diminution in muscle volume and strength, Source: Nieschlag E, Swerdloff R, Behre HM, Gooren LJ, Kaufman JM, Legros JJ, Lunenfeld B, Morley JE, Schulman C, Wang C, Weidner W, Wu FC. Investigation, treatment and monitoring of late-onset hypogonadism in males ISA, ISSAM, and EAU recommendations. European Urology. 2005;48:1 4.
15 What are the symptoms of late-onset hypogonadism? (ii) (5) Increase in visceral fat, (6) Decrease in body hair and skin alterations, (7) Decreased bone mineral density resulting in osteopenia, osteoporosis and increased risk of bone fractures. Source: Nieschlag E, Swerdloff R, Behre HM, Gooren LJ, Kaufman JM, Legros JJ, Lunenfeld B, Morley JE, Schulman C, Wang C, Weidner W, Wu FC. Investigation, treatment and monitoring of late-onset hypogonadism in males ISA, ISSAM, and EAU recommendations. European Urology. 2005;48:1 4.
16 What is the definition of late-onset hypogonadism? Many definitions: LOH is defined as a total testosterone level <300 ng/dl combined with the presence of three sexual symptoms: Decreased frequency of morning erections Erectile dysfunction Decreased frequency of sexual thoughts Source: Rivas AM, Mulkey Z, Lado-Abeal J, Yarbrough S. Diagnosing and managing low serum testosterone. Proc (Bayl Univ Med Cent) Oct;27(4):321-4.
18 Does male menopause (manopause, male climacteric, late-onset hypogonadism) actually occur? FACT: Total and free T decline w/ incr. age Symptoms of hypogonadism: ~ lack specificity & can be accounted for by other comorbidities: chronic illness, depression, etc. It is likely that LOH does really occur (as does normal aging) Diagnosis of LOH: Symptoms (+) low total T if total T: WNL --- > measure free T
19 How common is late-onset hypogonadism? The actual prevalence of hypogonadism has been estimated to be 39% in men aged 45 years or older presenting to primary care offices in the United States. Source: Rivas AM, Mulkey Z, Lado-Abeal J, Yarbrough S. Diagnosing and managing low serum testosterone. Proc (Bayl Univ Med Cent) Oct;27(4): Massachusetts Male Aging Study: Total T: <400 ng/dl (+) 3 signs/symptoms of low T: Prevalence of 6% to 12%. Source: O Donnell AB, Araujo AB, McKinlay JB. The health of normally aging men: The Massachusetts Male Aging Study ( ). Exp Gerontol 2004;39(7):
20 When should testosterone replacement be considered in symptomatic men? Total T: <230 mg/dl Tx ed men usually benefit >350 mg/dl Tx not required mg/dl Measure free T or BAT (especially for obese men) International Society of Andrology (ISA) International Society for the Study of Aging Male (ISSAM) European Association of Urology (EAU) European Academy of Andrology (EAA) American Society of Andrology (ASA) Wang C, Nieschlag E, Swerdloff R, Behre HM, Hellstrom WJ, Gooren LJ, Kaufman JM, Legros JJ, Lunenfeld B, Morales A, Morley JE, Schulman C, Thompson IM, Weidner W, Wu FC. Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA and ASA recommendations. Eur J Endocrinol Nov;159(5):
21 What are the economics of pharmacologic treatment of sexual dysfunction or androgen deficiency?
22 Worldwide Viagra revenue 2013: $1.881 billion
23 Annual testosterone revenue in U.S. 2013: $2.4 billion Projected*: 2018: $3.8 billion * Prior to March 3, 2015 FDA warning
24 What is the impact on laboratory services for requests for testosterone measurements? Study group: 321, y/o men; 2009 to Result: 3.2% had a testosterone measurement for any reason! P Hz of testing: 2.5% 3.6% < % incr. in 3 yrs Malik RD, Lapin B, Wang CE, Lakeman JC, Helfand BT. Are we testing appropriately for low testosterone?: characterization of tested men and compliance with current guidelines. J Sex Med Jan;12(1): in 5 men treated w/ T: normal T - Men treated by endocrinologists & urologists: more Hz ly have a low T Baillargeon J, Urban RJ, Kuo YF, Holmes HM, Raji MA, Morgentaler A, Howrey BT, Lin YL, Ottenbacher KJ. Screening and monitoring in men prescribed testosterone therapy in the u.s., Public Health Rep Mar- Apr;130(2):
25 What are the risks of testosterone therapy? Adverse androgen effects: - Increased aggression/behavior changes - Polycythemia - Prostate enlargement - Venous thrombo-embolism - Dyslipidemia - Hypertension - AMI, stroke
26 March 3, 2015 FDA warning! Hazard ratios for MI, stroke and/or death:
27 How should testosterone-treated men be monitored? Lab Testosterone Hb/Hct Lipids AST PSA Semen analysis Comment Monitoring Risk of polycythemia Risk of dyslipidemia Risk of hepatotoxicity Concern regarding risk of prostate cancer If infertility is present: reduced sperm Non-Lab BP DRE DexaScan Salt retention, incr. BP Concern regarding risk of prostate cancer BMD should incr. w/ T tx Best Pract Res Clin Endocrinol Metab Jan;29(1): doi: /j.beem Epub 2014 Oct 2. Current topics in testosterone replacement of hypogonadal men. Nieschlag E. Author information Abstract All forms of hypogonadism - primary, secondary and late-onset - require testosterone substitution. The indication is given when the patient presents with symptoms of androgen deficiency and the serum testosterone levels are below normal. Several testosterone preparations and modes of application are available of which those producing physiologic serum levels should be preferred e.g. preferentially transdermal gels and long-acting intramuscular testosterone undecanoate. Testosterone substitution must be monitored at regular intervals, best at 3, 6 and 12 months after initiation and then annually. Parameters for surveillance include well-being, libido and sexual activity, measurement of serum testosterone levels, haemoglobin and haematocrit, PSA and digital rectal examination, and, biannually, bone mineral density. Testosterone has positive effects on comorbidities such as obesity, metabolic syndrome, diabetes type II, cardiovascular diseases and osteoporosis.
28 Does testosterone therapy benefit older men? (i) Kunelius P, Lukkarinen O, Hannuksela ML, Itkonen O, Tapanainen JS. The effects of transdermal dihydrotestosterone in the aging male: a prospective, randomized, double blind study. J Clin Endocrinol Metab Apr;87(4):
29 Does testosterone therapy benefit older men? (ii) Corona G, Rastrelli G, Maggi M. Diagnosis and treatment of late-onset hypogonadism: systematic review and meta-analysis of TRT outcomes. Best Pract Res Clin Endocrinol Metab Aug;27(4): Late-onset hypogonadism (LOH) is a relatively common conditions affecting the aging male. The aim of this review is to summarize the available evidence regarding LOH and its interaction with general health. LOH is often comorbid to obesity and several chronic diseases. For this reason lifestyle modifications should be strongly encouraged in LOH subjects with obesity, type 2 diabetes mellitus (T2DM) and metabolic syndrome (MetS) and good treatment balance of chronic diseases. Medical therapy of LOH should be individualized depending on the etiology of the disease and the patient's expectations. Available evidence seems to suggest that testosterone replacement therapy is able to improve central obesity (subjects with MetS) and glycometabolic control (patients with MetS and T2DM), as well as to increase lean body mass (HIV, chronic obstructive pulmonary disease), along with insulin resistance (MetS) and peripheral oxygenation (chronic kidney diseases). However,... it should be recognized that the number of studies on benefits of T supplementation is too limited to draw final conclusions. Longer and larger studies are needed to better clarify the role of TRT in such chronic conditions.
30 Caveat emptor (Let the buyer beware... ) Corona G, Rastrelli G, Maseroli E, Forti G, Maggi M. Sexual function of the ageing male. Best Pract Res Clin Endocrinol Metab Aug;27(4): With the progressive increase in the proportion of older people, there is an increasing interest in characterizing the modifications of sexual health and the effect of its perturbations as a function of the aging process. The aim of this review is to summarize the available evidence regarding the age-dependent modifications of male sexual function and their interaction with general health and age-dependent modification of endocrine function. Elderly patients are often affected by multiple organic diseases which can interfere with sexual function. Despite this evidence, several studies have indicated that, with advancing age, normal erections are not an absolute prerequisite to remain sexually active. Good physical health, the availability of a partner, and a regular and stable pattern of sexual activity earlier in life predict the maintenance of sexual activity in old age. Conversely, there are no convincing data that hormonal changes, associated with aging, have a primary role in underlying changes in sexual function in healthy aging men. Nonetheless, sexual dysfunctions especially in elderly people are poor investigated. Asking about sexual health remains difficult or embarrassing for many primary care physicians. In addition, many patients find it difficult to raise sexual issues with their doctor. This situation often results in sexual issues not being adequately addressed thus resulting in depression, social withdrawal and delayed diagnosis of underlying medical conditions often resulting in forthcoming cardiovascular events. Education and permission from a health care professional may help to alter such misconceptions. Information from physicians regarding normal age-related changes in sexuality and encouragement, together with advice on how to continue meaningful sexual relations, may play a key role in altering such negative attitudes.
Point-Counterpoint: Late Onset Hypogonadism (LOH) We are Under-diagnosing and Treating Men with LOH LOH is a Non-existent Disease ~ Robert E. Donohue, MD Late Onset Hypogonadism LOH: underdx. & undertx
Evaluation and Treatment of Primary Androgen Deficiency Syndrome in Male Patients Jeff Unger, MD Director Chino Medical Group Diabetes and Headache Intervention Center Chino, California January 16, 2008
Male Androgen Replacement Mitchell Sorsby, MD June 19, 2010. QUESTION # 1 Which of the following is not a symptom associated with low T levels? a) decreased libido b) erectile dysfunction c) depression
Late onset Hypogonadism Dr KhooSay Chuan Department of Urology Penang General Hospital Late onset hypogonadism(loh) Definition LOH age associated testoteronedeficiency syndrome (TDS) Male menopause, andropause,
Recognizing and Managing Testosterone Deficiency J. Bruce Redmon, M.D. Professor Division of Endocrinology Departments of Medicine and Urologic Surgery Disclosure Information I have no financial relationships
Testosterone Therapy in Men An update SANDEEP DHINDSA Associate Professor of Medicine Director, Division of Endocrinology and Metabolism, Saint Louis University, St. Louis, MO Presenter Disclosure None
Late Onset Hypogonadism Toh Charng Chee Hospital Selayang Introduction Although suppressed serum testosterone (T) is common in ageing men, only a small proportion of them develop the genuine syndrome of
4 4:4pm Testosterone Therapy: Examining the Evidence SPEAKER Culley Carson, MD Presenter Disclosure Information The following relationships exist related to this presentation: Culley Carson, MD: Consultant
Endocrine Update 2016 Mary T. Korytkowski MD Division of Endocrinology University of Pittsburgh Disclosure of Financial Relationships Mary Korytkowski MD Honoraria British Medical Journal Diabetes Research
ORIGINAL PAPER DOI: 10.4081/aiua.2014.1.26 Present and future association between obesity and hypogonadism in Italian male Valentina Boddi 1, Valeria Barbaro 2, Paul Mc Nieven 3, Mario Maggi 1, Carlo Maria
www.kjurology.org DOI:10.4111/kju.2011.52.6.416 Sexual Dysfunction Correlation between Serum Total Testosterone and the AMS and IIEF Questionnaires in Patients with Erectile Dysfunction with Testosterone
Depression and Sexuality in Aging Men Prof. Dr. Michael Zitzmann Andrologist, Endocrinologist, Diabetologist Sexual Medicine (FECSM) Clinical Andrology / Centre for Reproductive Medicine and Andrology,
Take-Home Messages: Androgens Anthony J. Bella MD, FRCSC Greta and John Hansen Chair in Men s Health Research Division of Urology, Department of Surgery University of Ottawa SUMMARY SLAMS Symposium Clinical
www.kjurology.org http://dx.doi.org/10.4111/kju.2013.54.9.619 Sexual Dysfunction/Male Infertility Serum Total Testosterone Level and Identification of Late-Onset Hypogonadism: A Community-Based Study Sungmin
Effects of Hormone Therapy on the Metabolic Syndrome and Cardiovascular Disease Micol S. Rothman, MD Associate Professor of Medicine Endocrinology, Diabetes and Metabolism Clinical Director Metabolic Bone
THE RECEPTOR Message from the Chair Hubert Vesper, PhD, Centers for Disease Control and Prevention Greetings! The 2015 AACC Annual Meeting begins very soon and I would like to take this time to encourage
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.31 Subject: Testosterone Topical Page: 1 of 9 Last Review Date: September 23, 2016 Testosterone topical
SPECIAL ARTICLE Adult-Onset Hypogonadism Mohit Khera, MD, MBA, MPH; Gregory A. Broderick, MD; Culley C. Carson III, MD; Adrian S. Dobs, MD, MHS; Martha M. Faraday, PhD; Irwin Goldstein, MD; Lawrence S.
Alternative management of hypogonadism Tamoxifen Emmanuele A. Jannini, MD Tor Vergata University of Rome ITALY email@example.com What hypogonadism is? What hypogonadism is? It is an empty glass The two
guidelines in focus Martits AM et al. Late-onset hypogonadism or ADAM: diagnosis Hipogonadismo masculino tardio ou DAEM: diagnóstico Authorship: Brazilian Society of Endocrinology, Brazilian Society of
Metastatic prostate carcinoma Lee Say Bob July 2017 Scenario A 58 year old gentleman presents with PSA 200 ng/ml with hard prostate and bone mets. LUTS but upper tracts are normal with normal RP. history
Review Article Andropause: Current concepts Parminder Singh Division of Endocrinology, Dayanand Medical College and Hospital, Ludhiana, Punjab, India ABSTRACT Andropause or late-onset hypogonadism is a
ANDROGEN DEFICIENCY A GUIDE TO MALE HORMONES A BOOKLET IN THE SERIES OF CONSUMER GUIDES ON MALE REPRODUCTIVE HEALTH FROM First published in July 2003 by Andrology Australia 5th Edition, December 2015 Copyright
Detection of Hypogonadism and Applying Testosterone Replacement Therapy George R. Simms, M.D. PharmCon is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.33 Subject: Testosterone Injection Implant Page: 1 of 10 Last Review Date: March 17, 2017 Testosterone
ADULT UROLOGY PREVALENCE OF PROSTATE CANCER AMONG HYPOGONADAL MEN WITH PROSTATE-SPECIFIC ANTIGEN LEVELS OF 4.0 ng/ml OR LESS ABRAHAM MORGENTALER AND ERNANI LUIS RHODEN ABSTRACT Objectives. To determine
DOI: 10.5114/pm.2015.49998 Prz Menopauzalny 2015; 14(1): 1-6 Featured paper Andropause state of the art 2015 and review of selected aspects Grzegorz Jakiel 1, Marta Makara-Studzińska 2, Michał Ciebiera
EFFICACY AND SAFETY OF TESTOSTERONE THERAPY FOR LATE-ONSET HYPOGONADISM: AN UPDATE Matthew Ho, PGY-2 Department of Urologic Sciences University of British Columbia OBJECTIVES 1. Review the characteristics
Article Sexual dysfunction in men with diabetes Lesley Mills Citation: Mills L (2015) Sexual dysfunction in men with diabetes. Journal of Diabetes Nursing 19: 332 8 Article points 1. Sexual dysfunction
Research Subcutaneous estrogen replacement therapy. Jones SC. Journal of Reproductive Medicine March, 2004; 49(3):139-142. Department of Obstetrics and Gynecology, Keesler Medical Center, Keesler Air Force
Recommendations on the diagnosis, treatment and monitoring of hypogonadism in men The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters.
Georges A. de Boccard, M.D. Consultant Urologist F.E.B.U. Sexual function and dysfunction in men Training in Reproductive Health Research Geneva Foundation for Medical Education and Research Geneva March
TESTOGEL 50 mg, gel in sachet Testosterone Read all of this leaflet carefully before you start using this medicine because it contains important information for you. - Keep this leaflet. You may need to
Fundamentals of Testosterone Production in Men Dr. HHJ Leliefeld Bruges, Belgium 25-26 September, 2014 PRISM IV Why should we know? Essential for understanding the ratio of diagnosis and treatment of :
OCP OF NEW GENERATION - FOCUS ON DROSPIRENONE (Drospirenone 3 mg +Ethinyl estradiol 30mcg) Way Past Just Contraception Rasmin - Composition An OC formulation based on drospirenone Each calender pack contains
One Day Hormone Check Patient: EMILY TEST DOB: January 18, 1948 Sex: F MRN: 0000000004 Order Number: J5070009 Completed: March 07, 2014 Received: March 07, 2014 Collected: March 07, 2014 Alec Smart, ND
www.kjurology.org http://dx.doi.org/10.4111/kju.2011.52.11.725 Review Article Diagnosis and Treatment of Sexual Dysfunctions in Late-Onset Hypogonadism Jin Wook Kim, Du Geon Moon Department of Urology,
RESTANDOL TESTOCAPS TM 40MG CAPSULES, SOFT Testosterone undecanoate Read all of this leaflet carefully before you start taking this medicine because it contains important information for you. Keep this
pissn: 2287-4208 / eissn: 2287-4690 World J Mens Health 2015 December 33(3): 130-142 http://dx.doi.org/10.5534/wjmh.2015.33.3.130 Review Article Testosterone Replacement Therapy and Cardiovascular Risk:
Practical Management of Steroids in Non-Endocrine Practice Dr Miguel Debono MD MRCP PhD Consultant Physician in Endocrinology and Honorary Senior Lecturer February 2016 Outline Epidemiology of steroids
IOSR Journal of Dental and Medical Sciences (IOSRJDMS) eissn: 22790853, pissn: 22790861.Volume 14, Issue 8 Ver. V (Aug. 2015), PP 109116 www.iosrjournals.org The Clinical relevance of serum testosterone
1 How do you diagnose low Testosterone in men? Low Testosterone can be diagnosed if you have 3 or more of the following symptoms: lack of libido fatigue insomnia erectile dysfunction (ED) depression loss
Hormones Nuts and Bolts Ron Rothenberg MD Power Point Slides All slides from my presentation will be available to you. They will be posted to website next week CaliforniaHealthspan.com Hormone Bio-Identical
Medical and recreational use Dr Joseph Ischia Urological surgeon Clinical and Research Fellow Austin Health, Melbourne, AUSTRALIA Vancouver Prostate Centre, Vancouver, CANADA Medical Erectile dysfunction
Boston University OpenBU Theses & Dissertations http://open.bu.edu Boston University Theses & Dissertations 2014 Evaluating the cardiovascular risk of testosterone replacement therapy in men with late-onset
Female androgen profiles by MS for PCOS patients CS Ho APCCMS 2010, Hong Kong 14 January 2010 873 women with increased serum androgens Androgen-secreting neoplasms 0.2% Classical CAH 0.6% Non-classical
HOW I DO IT How I Do It: Managing bone health in patients with prostate cancer Jack Barkin, MD Department of Surgery, University of Toronto, Humber River Hospital, Toronto, Ontario, Canada BARKIN J. How
Review Article Off label therapies for testosterone replacement Lorenzo DiGiorgio 1, Hossein Sadeghi-Nejad 2 1 Division of Urology, Rutgers New Jersey Medical School, Newark, NJ, USA; 2 Hackensack University
ORIGINAL ARTICLE Vol. 42 (x): 2016 July 4.[Ahead of print] doi: 10.1590/S1677-5538.IBJU.2016.0112 Clomiphene citrate treatment for late onset hypogonadism: rise and fall Marcelo Marconi 1, Renato Souper
CASE 4- Toy et al. CASE FILES: Obstetrics & Gynecology A 49-year-old woman complains of irregular menses over the past 6 months, feelings of inadequacy, vaginal dryness, difficulty sleeping, and episodes
Philip S. Zeitler MD. PhD Division of Endocrinology Children s Hospital Colorado Aurora, Colorado Primary testicular failure Central hormones responsible for onset of puberty are normal The testis itself
Polycystic Ovarian Syndrome (PCOS) for the Family Physician Barbara S. Apgar MD, MS Professor or Family Medicine University of Michigan Ann Arbor, Michigan Important references for PCOS Endocrine Society
2017Adult Male Preventive Health Guidelines Important Note Health Net s Preventive Health Guidelines provide Health Net members and practitioners with recommendations for preventive care services for the
Clinical Policy: Reference Number: CA.CP.MP.507 Effective Date: 1/12 Last Review Date: 7/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory and
Complications and comorbidities in children with Type 1 and Type 2 diabetes Evangelia Kalaitzoglou, MD October 27 th, 2017 Disclosures No relevant financial relationships to disclose Learning Objectives
Erectile Dysfunction (ED) after Radiotherapy (RT) for Prostate Cancer William M. Mendenhall, MD Meta-Analysis of Probability of Maintaining Erectile Function after Treatment of Localized Cancer Treatment
0021-972X/01/$03.00/0 Vol. 86, No. 6 The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright 2001 by The Endocrine Society COMMENTARY Androgen Replacement Therapy in the Aging Male
GENder Education and Care Interdisciplinary Support (GENECIS) Feminizing Medications for Patients with Gender Dysphoria Patient Information and Informed Consent and Assent for Minors Before using medications
0021-972X/99/$03.00/0 Vol. 84, No. 10 The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright 1999 by The Endocrine Society Pharmacokinetics, Efficacy, and Safety of a Permeation-
Hypogonadism and Testosterone: Who Needs Testosterone Replacement? Mikel Gray, PhD, PNP, FNP, CUNP, CCCN, FAANP, FAAN Professor School of Medicine, Department of Urology School of Nursing, Department of
An update for GPs on modern radiation therapy & hormones for prostate cancer A/Prof Jeremy Millar Director Radiation Oncology, Alfred Health Clinical lead Prostate Cancer Outcomes Registry, Monash University
Prevalence of Polycystic Ovarian Syndrome among urban adolescent girls and young women in Mumbai Principal Investigator Co- Investigators Consultant Collaborating Hospital Dr. Beena Joshi Dr. Srabani Mukherji
Preferred Care Partners HEDIS Technical Standards 1 HEDIS What is HEDIS HEDIS Overview Adults HEDIS Overview Pediatrics HEDIS is a registered trademark of the National Committee for Quality Assurance 2
PATIENT INFORMATION LEAFLET Testosterone Enantate 250mg/ ml Solution for Injection Testosterone Enantate Read all of this leaflet carefully before you start using this medicine because it contains important
Name and address of Centre CERTIFIED TRAINING CENTER OF THE EUROPEAN ACADEMY OF ANDROLOGY, BUDAPEST A. 1082 BUDAPEST, ULLOI UT 78/B. B. 1062 BUDAPEST, PODMANICZKY UTCA 109-111. Type of Centre University
Diabetes Day for Primary Care Clinicians Advances in Diabetes Care Elliot Sternthal, MD, FACP, FACE Chair New England AACE Diabetes Day Planning Committee Welcome and Introduction This presentation will:
Laboratory analysis of the obese child recommendations and discussion MacKenzi Hillard May 4, 2011 aka: What to do with Fasting Labs The Obesity Epidemic The prevalence of obesity in adolescents has tripled
Trial Title A double-blind, randomised, placebo-controlled study to evaluate the effect of an orally-dosed herbal formulation containing Testofen, on sexual function and performance in healthy males. Abbreviated
Testosterone Deficiency in Men Ron Rothenberg MD Relevant financial relationships in the past twelve months by presenter or spouse/partner: NA Equipment: NA Speakers Bureau: NA Stock Shareholder: NA Grant/Research
Presents 10 Essential Blood Tests PART 2 The Blood Chemistry Webinars With DR. DICKEN WEATHERBY Creator of the Blood Chemistry Software Heart Disease, Inflammation, & Essential Blood Tests #2 to #4: Fibrinogen,
DOI 10.1186/s40064-016-2531-8 RESEARCH Open Access Applying machine learning techniques to the identification of late onset hypogonadism in elderly men Ti Lu 1, Ya Han Hu 2*, Chih Fong Tsai 3, Shih Ping
Pharmacy Policy Class: Transgender Hormonal Treatment for Adults Line of Business: Medi-Cal Effective date: February 15, 2017 Revision date: February 15, 2017 This policy has been developed through review
Clinical Endocrinology (1999) 50, 57 62 Experience with transdermal testosterone replacement therapy for hypogonadal men Susan Parker and Mary Armitage Diabetes and Endocrine Unit, Royal ournemouth Hospital,
IMPROVING PATIENT CARE THROUGH ESOTERIC LABORATORY TESTING SEPTEMBER 2007 A Clinical Conundrum: The Diagnosis and Treatment of Androgen Deficiency in Older Men Testosterone replacement in young men with
Client Information for Informed Consent FEMINIZING MEDICATIONS FOR TRANSGENDER CLIENTS Before using medications to transition and feminize, you need to know the possible advantages, disadvantages and risks